In short
A new drug called Ivospemin, also known as SBP-101, is currently being studied in clinical trials for the treatment of metastatic pancreatic ductal adenocarcinoma. This article provides information about the ongoing research, including the drug's potential benefits, how it's being tested, and what patients might expect from participating in the trial.
At a glance
- Drug Name
- Ivospemin (SBP-101)
- Condition Studied
- Metastatic Pancreatic Ductal Adenocarcinoma
- Study Type
- Randomized, Double-Blind, Placebo-Controlled
- Treatment Combination
- Ivospemin + Nab-paclitaxel + Gemcitabine
- Primary Objective
- Compare overall survival between Ivospemin and placebo groups
- Secondary Objectives
- Progression-free survival, Objective response rate, Disease control rate, Duration of response, Quality of life changes
- Exploratory Measures
- Effects on CA19-9 and circulating tumor DNA levels
- Key Eligibility Criteria
- Adults with confirmed metastatic pancreatic ductal adenocarcinoma, previously untreated for metastatic disease
- Drug Characteristics
- Small molecule, polyamine metabolic inhibitor
- Administration Route
- Subcutaneous injection
What is IVOSPEMIN?
IVOSPEMIN, also known by its product code SBP-101, is a new medication being studied for the treatment of metastatic pancreatic ductal adenocarcinoma, a severe form of pancreatic cancer that has spread to other parts of the body. It is classified as a small molecule and polyamine metabolic inhibitor, which means it works by interfering with certain processes in cancer cells.
Medical Condition: Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic pancreatic ductal adenocarcinoma is a type of pancreatic cancer that has spread beyond the pancreas to other parts of the body. It is a serious and life-threatening condition that often requires aggressive treatment.
Clinical Trial Overview
A clinical trial is currently underway to evaluate the effectiveness of IVOSPEMIN in treating metastatic pancreatic ductal adenocarcinoma. This study is a randomized, double-blind, placebo-controlled trial, which means that participants are randomly assigned to receive either IVOSPEMIN or a placebo, and neither the patients nor the doctors know who is receiving which treatment.
How IVOSPEMIN Works
IVOSPEMIN is administered through subcutaneous injection, which means it is injected just under the skin. It is designed to work as a polyamine metabolic inhibitor, potentially interfering with processes that cancer cells need to grow and survive.
Eligibility Criteria
To participate in this study, patients must meet certain criteria, including:
- Having a confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma
- Being previously untreated for this condition
- Being at least 18 years old
- Having adequate bone marrow, liver, kidney, and blood clotting function
- Having a life expectancy of at least 3 months
There are also some conditions that would exclude a person from participating, such as:
- Having known BRCA1/2 gene mutations
- Taking metformin (a diabetes medication)
- Being pregnant or breastfeeding
- Having had major surgery within 4 weeks of starting the study treatment
It's important to note that these are just some of the criteria, and a healthcare provider would need to do a full evaluation to determine if someone is eligible for the study.
Treatment Combination
In this study, IVOSPEMIN is being tested in combination with two other cancer drugs: nab-paclitaxel and gemcitabine. These are standard treatments for metastatic pancreatic cancer. The study aims to see if adding IVOSPEMIN to this combination improves outcomes for patients.
Study Objectives
The main goal of this study is to compare overall survival between patients who receive IVOSPEMIN and those who receive a placebo, when combined with nab-paclitaxel and gemcitabine. Overall survival refers to how long patients live after starting the treatment.
Secondary objectives include comparing:
- Progression-free survival: The time until the cancer starts growing again or the patient dies
- Objective response rate: The percentage of patients whose tumors shrink or disappear
- Disease control rate: The percentage of patients whose disease doesn't worsen
- Duration of response: How long the cancer remains controlled
- Quality of life: How the treatment affects patients' overall well-being
- Safety and tolerability of IVOSPEMIN compared to placebo
Potential Benefits
If successful, IVOSPEMIN could potentially offer several benefits for patients with metastatic pancreatic ductal adenocarcinoma:
- Improved survival rates
- Better control of cancer growth
- Improved quality of life
- A new treatment option for a difficult-to-treat cancer
However, it's important to remember that these potential benefits are still being studied and are not guaranteed.
Safety Considerations
As with any new medication, safety is a key concern. The study is carefully monitoring patients for any side effects or adverse reactions. Some specific safety considerations include:
- Monitoring of bone marrow, liver, and kidney function
- Regular heart rhythm checks (ECG)
- Careful screening for any conditions that might make the treatment unsafe
Patients in the study are closely monitored by healthcare professionals to ensure their safety throughout the trial.